Previous 10 | Next 10 |
Iveric bio ( NASDAQ: ISEE ) signed a license agreement for the right to develop and commercialize new formulations of eye disorder drug candidate Zimura using DelSiTech's silica-based sustained release technology. Under the agreement, Iveric will pay DelSiTech ...
IVERIC bio, Inc. (Nasdaq: ISEE) and DelSiTech Ltd, announced today an exclusive global license agreement providing Iveric Bio with the right to develop and commercialize new formulations of Zimura ® (avacincaptad pegol) using DelSiTech’s silica-based sustained releas...
Today, we take our first look at ocular focused biotech IVERIC bio, Inc. The stock has seen some insider buying here in June and its primary asset Zumira seems on the path to commercialization. An investment analysis follows in the paragraphs below. For further details see: ...
IVERIC bio, Inc. (Nasdaq: ISEE) announced today a post-hoc analysis from the Zimura ® (avacincaptad pegol) GATHER1 clinical trial which explored enhanced Optical Coherence Tomography (OCT) image analysis to examine the effect of Zimura on change in Ellipsoid Zone (EZ) integ...
Three weeks ago, I suggested that the severe correction in biopharmaceutical stocks had ended. I expect the bottoming process to be choppy with a bias to the upside. The antecedent cause of the decline was the "Class of 2021 IPOs", which featured many companies with preclinical compou...
Shares of IVERIC Bio (NASDAQ:ISEE) have added 4.4% to $11.46 in Wednesday morning trading, after both Bank of America and Guggenheim initiated the stock with buy ratings. BofA's price target for ISEE is $18, representing a ~64% upside to the stock's last closing price of $10.98, whi...
IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Pravin U. Dugel, M.D., President, will participate in a fireside chat at the UBS Global Healthcare Conference 2022 on Monday, May 23, 2022, at 10:45 a.m. Eastern Time. Investors and the general public are invited to access the...
IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Pravin U. Dugel, M.D., President, will present a corporate overview at the H.C. Wainwright Global Investment Conference, being held from May 23-26, 2022. The on-demand presentation will be available for viewing beginning Tuesd...
Stifel has raised its price target on Iveric bio (NASDAQ:ISEE) by more than 25% to a Street high after the clinical-stage biotech announced data from a post-hoc analysis of a late-stage trial for Zimura, a candidate for the eye disease geographic atrophy (GA). The results analyzed the disease...
IVERIC bio, Inc. (ISEE) Q1 2022 Earnings Conference Call May 04, 2022, 08:00 AM ET Company Participants Kathy Galante - SVP of IR Glenn Sblendorio - CEO Pravin Dugel - President Keith Westby - COO David Carroll - CFO Dhaval Desai - Chief Development Officer Chris Simms - Chief Commercial Offi...
News, Short Squeeze, Breakout and More Instantly...
Astellas Completes Acquisition of Iveric Bio PR Newswire TOKYO and PARSIPPANY, N.J. , July 11, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura , "Astellas") today announced that it has successfully completed the acquisit...
Shares of IVERIC bio, Inc. (NASDAQ: ISEE) traded at a new 52-week high today and are currently trading at $39.73. So far today, approximately 1.78M shares have been exchanged, as compared to an average 30-day volume of 5.04M shares. IVERIC bio, Inc., a biopharmaceutical company, discovers and...
IVERIC bio, Inc. (NASDAQ: ISEE) has caught the attention of the investment community today with its bullish price action. The company's shares are currently up 1.93% on the day to $38.77. IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal disease...